| 2.34 0.04 (1.74%) | 08-12 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 3.03 | 1-year : | 3.54 |
| Resists | First : | 2.59 | Second : | 3.03 |
| Pivot price | 2.15 |
|||
| Supports | First : | 2.22 | Second : | 1.99 |
| MAs | MA(5) : | 2.2 |
MA(20) : | 2.17 |
| MA(100) : | 2.26 |
MA(250) : | 1.98  |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 64 |
D(3) : | 55.2 |
| RSI | RSI(14): 58.1 |
|||
| 52-week | High : | 3.43 | Low : | 0.4 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ HURA ] has closed Bollinger Bands are 61.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 21 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.52 - 2.53 | 2.53 - 2.53 |
| Low: | 2.26 - 2.27 | 2.27 - 2.28 |
| Close: | 2.32 - 2.34 | 2.34 - 2.35 |
TuHURA Biosciences, Inc. is an immuno-oncology firm that has reached the critical Phase 3 registration stage of clinical development. The company is dedicated to pioneering innovative technologies designed to effectively combat the mechanisms by which cancers develop resistance to existing immunotherapy treatments. Its operations are based in Tampa, Florida.
Sun, 09 Aug 2026
Enterprise value to EBIT forward of TuHURA Biosciences, Inc. – NASDAQ:HURA - tradingview.com
Thu, 06 Aug 2026
TuHURA Biosciences (HURA) Expected to Release Quarterly Earnings on Thursday - marketbeat.com
Wed, 22 Jul 2026
TuHURA Biosciences (NASDAQ:HURA) Stock Price Down 1.3% - Time to Sell? - marketbeat.com
Wed, 22 Jul 2026
TuHURA Biosciences to Present at Canaccord Genuity's 46th Annual Growth Conference - PR Newswire
Fri, 15 May 2026
TuHURA Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate Update - PR Newswire
Wed, 22 Apr 2026
TuHURA Biosciences Announces $50 Million Credit Facility and Royalty Transaction Extending Anticipated Cash Runway into 2028 - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 64 (M) |
| Shares Float | 40 (M) |
| Held by Insiders | 34.6 (%) |
| Held by Institutions | 11.2 (%) |
| Shares Short | 6,650 (K) |
| Shares Short P.Month | 7,760 (K) |
| EPS | -0.62 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.36 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -81.9 % |
| Return on Equity (ttm) | -187.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.46 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -27 (M) |
| Levered Free Cash Flow | -2 (M) |
| PE Ratio | -3.84 |
| PEG Ratio | 0 |
| Price to Book value | 6.49 |
| Price to Sales | 0 |
| Price to Cash Flow | -5.46 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|